Clinical validation of next-generation sequencing-based clonality assays for minimal residual disease tracking in multiple myeloma

被引：0
|
作者：
Lin, Chuanming
Jian, Qijie
Huang, Zoufang
Xie, Shuiling
Xin, Liuyan
Wu, Haiyan
Pang, Fei
Liao, Changfeng
Chen, Yijian
机构：
[1] Gannan Med Univ, Affiliated Hosp 1, Ganzhou, Peoples R China
[2] Shanghai OrigiMed Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20037
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Upgraded standardized minimal residual disease detection by next generation sequencing in multiple myeloma
    Yao, Qiumei
    Chim, James
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E175 - E176
  • [22] Next generation sequencing-based monitoring for minimal residual disease in acute myeloid leukemia
    Ok, Chi Young
    Salim, Alaa
    Luthra, Rajyalakshmi
    Patel, Keyur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S196 - S196
  • [23] PROGNOSTIC VALUE OF SEQUENCING-BASED MINIMAL RESIDUAL DISEASE DETECTION IN PATIENTS WITH MULTIPLE MYELOMA
    Sanchez-Vega Carrion, B.
    Ruiz, Y.
    Barrios, S.
    Maldonado, R.
    Marin, C.
    Rapado, I
    Ayala, R.
    Cedena, T.
    Paiva, B.
    Garcia-Sanz, R.
    Jimenez, C.
    Mateos, M., V
    Rosinol, L.
    Blade, J.
    San Miguel, J.
    Lahuerta, J. J.
    Martinez, L. J.
    HAEMATOLOGICA, 2015, 100 : 60 - 60
  • [24] Clinical Utilization of Next-Generation Sequencing-Based Clonality Assays for Immunoglobulin Heavy Chain in Evaluating Suspected B-Cell Proliferation
    Katerji, Hani
    Katerji, Roula
    Campbell, Andrew
    Rothberg, Paul
    Ding, Yi
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 152 : S134 - S135
  • [25] Next-generation sequencing for measuring minimal residual disease in AML
    Walter, Roland B.
    Appelbaum, Frederick R.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (08) : 473 - 474
  • [26] Next-generation sequencing for measuring minimal residual disease in AML
    Roland B. Walter
    Frederick R. Appelbaum
    Nature Reviews Clinical Oncology, 2018, 15 : 473 - 474
  • [27] IGH AND IGK CLONAL TRACKING FOR MINIMAL RESIDUAL DISEASE MONITORING IN MULTIPLE MYELOMA BY NEXT GENERATION SEQUENCING: A BOLOGNA EXPERIENCE
    Armuzzi, S.
    Martello, M.
    Borsi, E.
    Solli, V.
    Poletti, A.
    Agboyi, L.
    Vigliotta, I.
    Zamagni, E.
    Pantani, L.
    Rocchi, S.
    Mancuso, K.
    Tacchetti, P.
    Rizzello, I.
    Cavo, M.
    Terragna, C.
    HAEMATOLOGICA, 2020, 105 : S42 - S43
  • [28] Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR
    Yao, Qiumei
    Bai, Yinlei
    Kumar, Shaji
    Au, Elaine
    Orfao, Alberto
    Chim, Chor Sang
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [29] Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
    Ferla, Valeria
    Antonini, Elena
    Perini, Tommaso
    Farina, Francesca
    Masottini, Serena
    Malato, Simona
    Marktel, Sarah
    Stanghellini, Maria Teresa Lupo
    Tresoldi, Cristina
    Ciceri, Fabio
    Marcatti, Magda
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy
    Huang, Yue
    Zhao, Houli
    Shao, Mi
    Zhou, Linghui
    Li, Xiaoqing
    Wei, Guoqing
    Wu, Wenjun
    Cui, Jiazhen
    Chang, Alex H.
    Sun, Tao
    Hu, Yongxian
    Huang, He
    BONE MARROW TRANSPLANTATION, 2022, 57 (08) : 1350 - 1353
12345